Quality Check,peptide

The survodutide peptide sequence is at the heart of a groundbreaking therapeutic candidate for obesity and metabolic disorders. This peptide is a synthetic investigational peptide designed to act as a dual agonist, targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual action is key to its potential efficacy in reducing body weight in a dose-dependent and tolerable manner. Understanding the intricacies of its sequence is crucial for appreciating its mechanism of action and its potential applications.

At its core, survodutide is a 29-amino-acid peptide. The precise survodutide peptide sequence has been elucidated through extensive research and is represented in various forms, reflecting its complex structure. One commonly cited representation is H-Ac4c-QGTFTSDYSKYLDERAAKDFI-X-WLESA-NH2, where Ac4c stands for 1-Aminocyclobutane-1-carboxylic Acid, a non-natural amino acid that contributes to its stability and pharmacokinetic profile. The 'X' often denotes a glycine-serine linker, further connecting different elements of the molecule.

Another detailed depiction of the survodutide peptide sequence highlights its components: His-{1-Aminocyclobutanecarboxylic acid}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-T. This representation emphasizes the N-terminal modifications and the initial amino acids of the peptide chain. It's important to note that the sequence is not static and can be represented with slight variations depending on the source and the level of detail provided, such as (A chain) HXQGTFTSDY SKYLDERAAK DFIKWLESA and an associated (B chain) EGSGSGG with an amide bridge. The overall structure is often described as a COMPLETE amino acid sequence derived from synthetic origins.

The molecular formula of survodutide is C192H289N47O61, with a molecular weight of approximately 4231.63. Beyond the linear amino acid sequence, survodutide incorporates further modifications that enhance its therapeutic potential. It is an acylated peptide, typically featuring a C18 fatty acid conjugate. This acylation strategy, often involving a C18 diacid half-life extension motif such as {GGSGSG-γE-C18 di-acid}, significantly prolongs its duration of action, allowing for once-weekly administration via subcutaneous injection. This long-acting nature is a critical factor in its development for chronic conditions like obesity.

The mechanism of action of survodutide is rooted in its ability to act as a Glucagon-like peptide 1 receptor agonist and a glucagon receptor agonist. By simultaneously activating both the GLP-1 receptor and the glucagon receptor, survodutide leverages the distinct physiological effects of these hormones. The GLP-1 receptor activation is known for reducing appetite, enhancing satiety, and improving glycemic control. Concurrently, glucagon receptor activation plays a role in increasing energy expenditure. This synergistic effect is believed to be more potent for weight management than targeting either receptor alone.

The development of survodutide falls under the umbrella of novel peptide therapies for metabolic diseases. Its design is conceptually based on endogenous peptide oxyntomodulin, a hormone that also exhibits dual GLP-1 and glucagon receptor activity. The modifications made to the survodutide peptide sequence aim to optimize its binding affinity and efficacy at both receptors. Research has shown that survodutide is a 29-amino-acid peptide based on the glucagon amino acid sequence, with specific substitutions at certain positions to confer GLP-1 receptor activity, such as swaps at positions 18, 20, and 23, and a swap to exendin-4 at position 16. The sequence length is a critical factor influencing its stability, potency, and overall behavior within the body.

While survodutide (also identified by its development code BI 456906 and CAS Number 2805997-46-8, and potentially referred to as SUVN-G3031) is a promising candidate, it is important to note that it is an investigational peptide. Clinical trials, such as the SYNCHRONIZE-CVOT study, are underway to determine its cardiovascular safety and efficacy in individuals with obesity and increased cardiovascular risk. The survodutide peptide benefits are being rigorously evaluated in Phase 3 studies for people living with obesity and overweight, with and without co-existing conditions like diabetes and cardiovascular disease. The potential for survodutide peptide for weight loss is a primary focus, alongside its role in managing conditions like MASH (metabolic dysfunction-associated steatohepatitis).

The exploration